Last updated on May 2018

Emricasan an Oral Caspase Inhibitor in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension


Brief description of study

This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects with NASH cirrhosis and severe portal hypertension (defined as HVPG 12 mmHg as determined by the central reader assigned to this study). Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID, 25 mg BID, or 5 mg BID or matching placebo BID.

Clinical Study Identifier: NCT02960204

Contact Investigators or Research Sites near you

Start Over

Lisa Grubbs

Iowa Digestive Disease Center
Clive, IA United States